Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06507254 · ClinicalTrials.gov registry record · NA
Polyphenols and Cognitive Decline
A NA study of Cognitive Decline and Cognitive Dysfunction, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- NA
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT06507254: Recruiting NA study of Cognitive Decline and Cognitive Dysfunction, sponsored by University of California, Los Angeles.
NCT06507254 is a NA study of Cognitive Decline and Cognitive Dysfunction that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 300 participants, below the 1,145-participant average among 61 other Cognitive Decline trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06507254, a NA study of Cognitive Decline and Cognitive Dysfunction, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- NA
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
Globally, populations are aging thereby increasing healthcare burden, overall cognitive impairment, and dementia including Alzheimers diseases (AD). The lack of effective treatments makes it essential to develop new strategies for healthy cognitive aging, including interventions to slow or prevent cognitive decline. A traditional Mediterranean diet, rich in polyphenols (PPs), may prevent or delay the onset of cognitive dysfunction in older adults, preserving healthy brain structure and function, and lowering the risk of AD. These effects, mediated in part by gut microbiome-derived PP metabolites, highlight the role alterations in the brain-gut microbiome system play in neurodegeneration. Moreover, high levels of circulating phenyl-y-valerolactones, neuroprotective compounds, exclusively produced by gut microbiota from flavan-3-ol-rich foods (e.g., cocoa, tea, berries) are associated with delaying the onset of cognitive dysfunction in older adults. Intake of such PPs can also change gut microbial composition and function, altering the physiology of the hosts secondary bile acid (BA) pool, affecting regulatory and signaling functions in the brain as well as cognitive decline and AD. The investigators hypothesize that, in older adults with enhanced AD risk, dietary intake of PPs maintains healthier brain features and cognitive function, and that this beneficial effect is mediated by gut microbiota metabolites of PPs and BAs. In this multi-PI application by leaders in the field of brain-gut microbiome interactions, the investigators will conduct a year-long, multi-center, randomized double-blind placebo-controlled study in 300 older adults in the United States (validation sample of 100 from Northern Ireland) who are at enhanced risk of developing AD. Ultimately, the investigators will establish the protective effects of regular dietary PP intake on cognitive function and on brain-gut microbiome interactions, ideally allowing the development of effective dietary regimes
Primary Outcome
Measurement of metabolomics via stool specimen.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Polyphenol Supplement
- DIETARY_SUPPLEMENT Placebo Supplement
Study Locations (1)
California
- University of California, Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-01-09 |
| Est. Completion | 2029-12-31 |
| Phase | NA |
What NCT06507254 shows while recruiting
NCT06507254 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 1,145-participant average among 61 other Cognitive Decline trials with a reported enrollment target (74% lower).
The record links to 2 conditions, with Cognitive Decline appearing as the primary indexed condition, and to 2 interventions - of which Polyphenol Supplement is the first listed.
NCT06507254 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06507254 about?
NCT06507254 is a clinical study titled "Polyphenols and Cognitive Decline". Globally, populations are aging thereby increasing healthcare burden, overall cognitive impairment, and dementia including Alzheimers diseases (AD). The lack of effective treatments makes it essential to develop new strategies for healthy cognitive aging, including interventions to slow or prevent c...
What is the current status of trial NCT06507254?
This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2025-01-09. Estimated completion is 2029-12-31.
What conditions does trial NCT06507254 study?
This clinical trial studies the following conditions: Cognitive Decline, Cognitive Dysfunction.
What interventions are being tested in trial NCT06507254?
The interventions under investigation include: Polyphenol Supplement (DIETARY_SUPPLEMENT), Placebo Supplement (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06507254?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06507254 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Decline
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06507254's enrollment target sits among peer trials
300 16th of 61 higher than 43 of 61 other Cognitive Decline trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cognitive Decline trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
δ in Dementia Clinical Trials
RECRUITING · NA
-
mPATH for Low-income Older Adults
RECRUITING · NA
-
MindWalk Intervention for Older South Asian Caregivers of People With Cognitive Disabilities (CD)
RECRUITING · NA
-
Preventing Cognitive Decline by Reducing BP Target Trial
RECRUITING · NA
-
Essential Fats For Enhancing Cognitive Thinking (EFFECT) Study
RECRUITING · NA
-
Exercise Adherence and Cognitive Decline: Phase 2
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI